Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Agerelated Macular Degeneration (AMD) Who Received Anti-VEGF Agents (IRIS Registry)
Latest Information Update: 10 Nov 2021
Price :
$35 *
At a glance
- Drugs Aflibercept (Primary) ; Bevacizumab (Primary) ; Ranibizumab (Primary)
- Indications Wet age-related macular degeneration
- Focus Adverse reactions
- Acronyms IRIS Registry
- Sponsors Novartis Pharmaceuticals
- 10 Nov 2021 New trial record